Related Experiment Video
Updated: Aug 11, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Insights
Human protein C is a key regulator of blood clotting. Deficiencies, both inherited and acquired, are linked to severe thrombosis, highlighting its critical role in preventing dangerous blood clots.
Area of Science:
- Biochemistry
- Hematology
- Molecular Biology
Background:
- Human protein C is a critical anticoagulant protein.
- Congenital deficiencies of protein C are associated with a high risk of thromboembolic events.
- Protein C plays a vital role in regulating coagulation pathways.
Purpose of the Study:
- To investigate the role of human protein C in both congenital and acquired thrombotic states.
- To understand the clinical implications of protein C deficiency in various thrombotic conditions.
- To emphasize the importance of protein C in maintaining hemostatic balance.
Main Methods:
- Review of clinical cases with congenital protein C deficiencies.
- Analysis of protein C antigen and activity levels in patients with thrombotic complications.
- Correlation of protein C levels with the severity of disseminated intravascular coagulation (DIC).
Main Results:
- Congenital protein C deficiency, especially homozygous deficiency, leads to severe thrombosis like purpura fulminans in newborns.
- Patients with familial thrombotic complications exhibit abnormal protein C molecules or reduced levels.
- Acquired deficiencies, including those during DIC and postsurgical states, show decreased protein C levels correlating with thrombosis severity.
Conclusions:
- Human protein C is essential for preventing thrombosis in both congenital and acquired deficiency states.
- Maintaining adequate protein C levels is crucial for managing thromboembolic disorders.
- Protein C replacement therapy is vital for survival in severe congenital deficiencies.
Abstract:
Human protein C is the central protein of an important regulatory mechanism, as shown by the high incidence of thromboembolic complications in congenital deficiencies of protein C. Both abnormal molecules and half-normal levels of protein C antigen and activity have been found in patients with familial thrombotic complications. Newborn infants with congenital homozygous protein C deficiency develop catastrophic thrombosis (purpura fulminans) and will not survive beyond the neonatal period without protein C replacement. Individuals with systemic thrombosis have significantly decreased levels of protein C concomitant with the severity of the DIC. These studies suggest that protein C is important not only in the congenital deficiencies, but also in acquired deficiencies, such as during DIC or possibly the postsurgical hypercoagulable state.
More Related Videos
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism I: Introduction
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Pulmonary Embolism I: Introduction

